Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × INDUSTRY × lenvatinib × Clear all

Phase

Status

Completed 58 Active not recruiting 17 Recruiting 13 Terminated 5 Not yet recruiting 5 Unknown 2 Approved for marketing 2 Suspended 1 Enrolling by invitation 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 5 Gemcitabine 3 E 7107 2 Docetaxel 2 Carboplatin 2 Antibodies, Monoclonal 2 130-nm albumin-bound paclitaxel 2 trastuzumab biosimilar HLX02 1 taxane 1 resiniferatoxin 1 poly(I).poly(c12,U) 1 pegamotecan 1 palbociclib 1 lenvatinib 1 imisopasem manganese 1 icotinib 1 gusacitinib 1 famitinib 1 eniluracil 1 dabrafenib 1 cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1 cobimetinib 1 ammonium trichloro(dioxoethylene-O,O'-)tellurate 1 abivertinib 1 abiraterone 1 abarelix 1 Trastuzumab 1 Topotecan 1 Tomography, Optical Coherence 1 TPI-287 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡